Influenza

Cold-Adapted A/Len/47 Flu Vaccine Highly Stable

Published in Vaccine Weekly, September 4th, 1995

A U.S. Centers for Disease Control and Prevention (CDC) study confirms reports demonstrating the genetic stability and safety of reassortant live attenuated influenza vaccines made with the A/Leningrad/134/47/57 (H2N2) cold-adapted virus.

Live attenuated reassortant vaccines are widely used in Russia to prevent flu outbreaks. These vaccines are produced by reassortment of current epidemic viruses with attenuated cold-adapted (ca) strains selected for their ability to replicate at low temperatures.

"The A/Leningrad/134/47/57 (H2N2) strain (A/Len/47) was obtained by 47 sequential passages of the A/Leningrad/134/57 wild-type virus (A/Len/wt) in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1995-09-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry